Dylan Caplan

M&A & Strategic Transactions

• Dexcel Pharma in connection with its acquisition of U.S. rights to Zubsolv
• Kira Pharmaceuticals in connection with its merger with Jasper Therapeutics
• Axogen, Inc. in the negotiation of a US$75 million term loan facility with Oberland Capital Management LLC, including equity conversion features
• Atrin Pharmaceuticals Inc. in connection with its merger with Aprea Therapeutics, Inc.
• PDS Biotechnology Corporation in connection with its merger with Edge Therapeutics
• Aclaris Therapeutics, Inc. in its sale of a portion of future royalty payments and certain milestones to OMERS
• Liquidia Corporation in connection with its entry into a Revenue Interest Financing Agreement with HealthCare Royalty for a total investment amount of up to US$100 million
• Adaptive Biotechnologies in connection with its non-dilutive royalty financing with OrbiMed for up to US$250 million
• COEUS, a multi-specialty, commercially aligned consultancy company, in its sale to Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial solutions, and learning and development
• Predictive Oncology in its US$343.5 million digital asset treasury launch
• Graham Partners on the formation of Quantive Intelligence through the acquisitions of TechData Service Company, LLC, LLX Solutions, LLC, and R Square Technology, Inc.
• Celero in its US$625 million acquisition by Deluxe Corporation

Capital Markets

• Aprea Therapeutics, Inc., a clinical-stage precision oncology company, in multiple capital markets transactions, including a US$34 million PIPE
• PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company, in multiple capital markets transactions
• Iovance Biotherapeutics, Inc. in connection with multiple capital markets transactions, including a US$603.7 million follow-on public offering of common stock

Emerging Companies & Venture Capital

• Regent Craft Inc. in connection with its multiple offerings, inclusive of its US$240 million Series B financing
• ZeroEyes, Inc., a developer of an AI-powered weapon detection platform, in its Series A and Series B financings
• BillingPlatform in its US$90 million growth equity investment from FTV Capital
• Real Capital Analytics in a US$115 million growth equity investment from Susquehanna Growth Equity